Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke
- PMID: 17143191
- DOI: 10.1097/01.hjh.0000254376.80864.d3
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke
Abstract
Objective: The effects of candesartan treatment starting early (3 h) and delayed (24 h) after middle cerebral artery occlusion (MCAO) with reperfusion was investigated in normotensive rats.
Methods: Subcutaneous treatment with candesartan (0.3 and 3 mg/kg) or vehicle was initiated 3 or 24 h after the onset of MCAO and continued for seven consecutive days (n=20 per group and timepoint). Neurological outcome was evaluated daily using two different scoring systems. Infarct and oedema volumes were determined in rats 2 or 7 days after MCAO. Mean arterial, systolic and diastolic blood pressures were recorded before and after the application of candesartan.
Results: Mean arterial, systolic and diastolic blood pressures were markedly decreased with the high dose, but only moderately decreased with the low dose of candesartan. Vehicle-treated rats showed marked neurological deficits 24 h after MCAO, which gradually improved with time. Candesartan improved neurological outcomes at all timepoints only when treatment was started 3, but not 24 h after MCAO. The infarct volume was reduced on days 2 and 7 after MCAO in rats treated with the low but not the high dose of candesartan.
Conclusion: The present study demonstrates that only an early but not a delayed onset of treatment with candesartan exerts neuroprotection after focal ischaemia. The degree of neurological impairments did not correlate with the infarct volume, which was reduced only after the low dose of candesartan. The high dose of candesartan failed to reduce the infarct volume, probably because of an excessive blood pressure decrease.
Similar articles
-
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.J Hypertens. 2008 Mar;26(3):544-52. doi: 10.1097/HJH.0b013e3282f2dac9. J Hypertens. 2008. PMID: 18300867
-
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.Hypertens Res. 2009 Jul;32(7):548-53. doi: 10.1038/hr.2009.69. Epub 2009 May 8. Hypertens Res. 2009. PMID: 19424281
-
Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.J Hypertens. 2007 Apr;25(4):855-9. doi: 10.1097/HJH.0b013e3280149708. J Hypertens. 2007. PMID: 17351379
-
Inhibiting angiotensin receptors in the brain: possible therapeutic implications.Curr Med Res Opin. 2003;19(5):449-51. doi: 10.1185/030079903125001974. Curr Med Res Opin. 2003. PMID: 13678486 Review.
-
Neurological protection provided by candesartan: reviewing the latest study results.Curr Med Res Opin. 2003;19(5):445-8. doi: 10.1185/030079903125001974. Curr Med Res Opin. 2003. PMID: 13678485 Review.
Cited by
-
The promyelocytic leukemia zinc finger (PLZF) protein exerts neuroprotective effects in neuronal cells and is dysregulated in experimental stroke.Brain Pathol. 2011 Jan;21(1):31-43. doi: 10.1111/j.1750-3639.2010.00427.x. Brain Pathol. 2011. PMID: 20731660 Free PMC article.
-
The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies.Brain Sci. 2020 Mar 7;10(3):153. doi: 10.3390/brainsci10030153. Brain Sci. 2020. PMID: 32156050 Free PMC article. Review.
-
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?Naunyn Schmiedebergs Arch Pharmacol. 2017 Sep;390(9):949-959. doi: 10.1007/s00210-017-1395-y. Epub 2017 Jul 2. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28669009
-
Cell-based and pharmacological neurorestorative therapies for ischemic stroke.Neuropharmacology. 2018 May 15;134(Pt B):310-322. doi: 10.1016/j.neuropharm.2017.08.036. Epub 2017 Sep 1. Neuropharmacology. 2018. PMID: 28867364 Free PMC article. Review.
-
The role of angiotensin II receptors in stroke protection.Curr Hypertens Rep. 2012 Jun;14(3):202-8. doi: 10.1007/s11906-012-0257-8. Curr Hypertens Rep. 2012. PMID: 22447068 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical